Endotis and Catalent to develop oral formulations of synthetic oligosaccharides
Endotis Pharma, a French biopharmaceutical company specialising in the development of synthetic oligosaccharides (small-glyco drugs) in thrombosis and cancer, is to collaborate with Catalent of the US to develop oral formulations of small-glyco drugs and will focus on the preclinical development of Endotis" EP37151 compound.
Endotis Pharma, a French biopharmaceutical company specialising in the development of synthetic oligosaccharides (small-glyco drugs) in thrombosis and cancer, is to collaborate with Catalent of the US to develop oral formulations of small-glyco drugs and will focus on the preclinical development of Endotis" EP37151 compound.
EP37151 is an oral synthetic oligosaccharide anticoagulant, which, as an indirect factor Xa inhibitor, acts through antithrombin activation. The companies expect to initiate a Phase I clinical trial during the second quarter of 2010.
"The oral formulation of synthetic oligosaccharides is a major breakthrough that will allow us fully to exploit the therapeutic potential of small-glyco drugs which, to date, have only been administered intravenously or subcutaneously," said Maurice Petitou head of pre-clinical research and development at Endotis Pharma.
Charles Woler, Endotis Pharma's ceo, added: "The technology developed with Catalent is a major step forward for Endotis and will unlock therapeutic indications for our small-glyco drugs in thrombosis and other therapeutic areas."
